Journal of Cystic Fibrosis

Article	Citations
Worldwide rates of diagnosis and effective treatment for cystic fibrosis	109
A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis	100
Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease	95
The global impact of SARS-CoV-2 in 181 people with cystic fibrosis	71
Updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID)	62
Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis	62
Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection	60
Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials	59
Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study	57
Outcomes of pregnancy in women with cystic fibrosis (CF) taking CFTR modulators – an international survey	57
Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis–data from the European cystic fibrosis society patient registry	56
Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR	52
Functional rescue of c.3846G>A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of action	51
Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation	50
Cystic fibrosis related diabetes in Europe: Prevalence, risk factors and outcome; Olesen et al	49
Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis	46
Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Atalur	45
New approaches to genetic therapies for cystic fibrosis	45
Investigating transmission of Mycobacterium abscessus amongst children in an Australian cystic fibrosis centre	44
Effect of one-year lumacaftor–ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients	44
Modeling pulmonary cystic fibrosis in a human lung airway-on-a-chip	43
Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy	43
Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids	43
Elexacafator/tezacaftor/ivacaftor resolves subfertility in females with CF: A two center case series	41
Elexacaftor-Tezacaftor- Ivacaftor improves sinonasal outcomes in cystic fibrosis	41

Development of the gut microbiota in early life: The impact of cystic fibrosis and antibiotic treatment	41
Patient and family perceptions of telehealth as part of the cystic fibrosis care model during COVID-19	41
The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis	40
Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients	39
PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy	38
Integrating the multiple breath washout test into international multicentre trials	38
Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis	37
Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis	37
Dose adjustments of Elexacaftor/Tezacaftor/Ivacaftor in response to mental health side effects in adults with cystic fibrosis	36
Amplifiers co-translationally enhance CFTR biosynthesis via PCBP1-mediated regulation of CFTR mRNA	35
A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous	35
The impact of the COVID-19 pandemic on the emotional well-being and home treatment of Belgian patients with cystic fibrosis, including transplanted patients and paediatric patients	35
Amikacin liposome inhalation suspension for chronic Pseudomonas aeruginosa infection in cystic fibrosis	34
Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy	34
Projecting the impact of delayed access to elexacaftor/tezacaftor/ivacaftor for people with Cystic Fibrosis	33
Whole-blood transcriptomic responses to lumacaftor/ivacaftor therapy in cystic fibrosis	33
A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus	33
Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis	32
Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020	32
Forskolin-induced swelling of intestinal organoids correlates with disease severity in adults with cystic fibrosis and homozygous F508del mutations	31
The fungal airway microbiome in cystic fibrosis and non-cystic fibrosis bronchiectasis	31
A survey of the prevalence, management and outcome of infants with an inconclusive diagnosis following newborn bloodspot screening for cystic fibrosis (CRMS/CFSPID) in six Italian centres	31
Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation	31
The impact of CFTR modulator therapies on CF airway microbiology	30
Telehealth use in cystic fibrosis during COVID-19: Association with race, ethnicity, and socioeconomic factors	30
A restructuring of microbiome niche space is associated with Elexacaftor-Tezacaftor-Ivacaftor therapy in the cystic fibrosis lung	30
Testicular pain following initiation of elexacaftor/tezacaftor/ivacaftor in males with cystic fibrosis	30
Changes in LCI in F508del/F508del patients treated with lumacaftor/ivacaftor: Results from the prospect study	29
Decreased survival in cystic fibrosis patients with a positive screen for depression	29
Extended-culture and culture-independent molecular analysis of the airway microbiota in cystic fibrosis following CFTR modulation with ivacaftor	29
Recommended shielding against COVID-19 impacts physical activity levels in adults with cystic fibrosis	28
Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI	28
Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del	28
Emerging preclinical modulators developed for F508del-CFTR have the potential to be effective for ORKAMBI resistant processing mutants	28
Mutation-specific dual potentiators maximize rescue of CFTR gating mutants	28
Alternative chloride transport pathways as pharmacological targets for the treatment of cystic fibrosis	28
Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation	27
Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy	26
Tobacco smoke exposure and socioeconomic factors are independent predictors of pulmonary decline in pediatric cystic fibrosis	26
Asymptomatic case of Covid-19 in an infant with cystic fibrosis	26
Relationship between airway dysbiosis, inflammation and lung function in adults with cystic fibrosis	25
Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study	25
Factors influencing the acquisition and eradication of early Pseudomonas aeruginosa infection in cystic fibrosis	25
Postprandial changes in gastrointestinal function and transit in cystic fibrosis assessed by Magnetic Resonance Imaging	25
Peak OGTT glucose is associated with lower lung function in young children with cystic fibrosis	25
Supersonic shear-wave elastography and APRI for the detection and staging of liver disease in pediatric cystic fibrosis	24
Overweight and obesity in adults with cystic fibrosis: An Italian multicenter cohort study	24
Significant functional differences in differentiated Conditionally Reprogrammed (CRC)- and Feeder-free Dual SMAD inhibited-expanded human nasal epithelial cells	24
Pregnancy in cystic fibrosis: Review of the literature and expert recommendations	24
Disruption of the extracellular polymeric network of Pseudomonas aeruginosa biofilms by alginate lyase enhances pathogen eradication by antibiotics	23

Functional Restoration of CFTR Nonsense Mutations in Intestinal Organoids	23
Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor	23
Use of a mobile application for self-management of pancreatic enzyme replacement therapy is associated with improved gastro-intestinal related quality of life in children with Cystic Fibrosis	23
Building global development strategies for cf therapeutics during a transitional cftr modulator era	23
Glucose abnormalities detected by continuous glucose monitoring are common in young children with Cystic Fibrosis	22
Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function	22
Short-term effect of elexacaftor-tezacaftor-ivacaftor on lung function and transplant planning in cystic fibrosis patients with advanced lung disease	22
Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients	22
Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices	22
The influence of CFTR complex alleles on precision therapy of cystic fibrosis	21
Baseline Cystic fibrosis disease severity has an adverse impact on pregnancy and infant outcomes, but does not impact disease progression	21
Obesity in Cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry	21
Biliary disease and cholecystectomy after initiation of elexacaftor/ivacaftor/tezacaftor in adults with cystic fibrosis	21
Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations	21
Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis	21
Abnormal glucose tolerance and lung function in children with cystic fibrosis. Comparing oral glucose tolerance test and continuous glucose monitoring	21
Genetic variation in CFTR and modifier loci may modulate cystic fibrosis disease severity	21
A comparison of clinic and home spirometry as longtudinal outcomes in cystic fibrosis	21
Impact of COVID-19 on mental health: Effects on screening, care delivery, and people with cystic fibrosis	21
Phages as immunomodulators and their promising use as anti-inflammatory agents in a cftr loss-of-function zebrafish model	20
Human cystic fibrosis monocyte derived macrophages display no defect in acidification of phagolysosomes when measured by optical nanosensors	20
Intestinal organoids for Cystic Fibrosis research	20
Current prices versus minimum costs of production for CFTR modulators	20
Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events	20
Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double‐blind, placebo‐controlled phase 1/2 clinical study	20
A smartphone application for reporting symptoms in adults with cystic fibrosis improves the detection of exacerbations: Results of a randomised controlled trial	20
Interplay between host-microbe and microbe-microbe interactions in cystic fibrosis	19
Prevalence of unmet palliative care needs in adults with cystic fibrosis	19
Psychological distress in adults with and without cystic fibrosis during the COVID-19 lockdown	19
SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis	19
Tobacco smoke exposure limits the therapeutic benefit of tezacaftor/ivacaftor in pediatric patients with cystic fibrosis	19
Cardiovascular complications in cystic fibrosis: A review of the literature	19
CFTR modulators increase risk of acute pancreatitis in pancreatic insufficient patients with cystic fibrosis	19
Patient and family experience of telehealth care delivery as part of the CF chronic care model early in the COVID-19 pandemic	19
Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR	18
Towards next generation therapies for cystic fibrosis: Folding, function and pharmacology of CFTR	18
Remote monitoring in telehealth care delivery across the U.S. cystic fibrosis care network	18
Average rate of lung function decline in adults with cystic fibrosis in the United Kingdom: Data from the UK CF registry	18
Challenges in the use of highly effective modulator treatment for cystic fibrosis	18
Clinical effect of lumacaftor/ivacaftor in F508del homozygous CF patients with FEV1 ≥ 90% predicted at baseline	17
Review of Gastrointestinal Motility in Cystic Fibrosis	17
Guidance for computed tomography (CT) imaging of the lungs for patients with cystic fibrosis (CF) in research studies	17
Changes in fecal microbiota with CFTR modulator therapy: A pilot study	17
Prospective longitudinal association between repeated multiple breath washout measurements and computed tomography scores in children with cystic fibrosis	17
Can exercise replace airway clearance techniques in cystic fibrosis? A survey of patients and healthcare professionals	17
Comparison of Cas9 and Cas12a CRISPR editing methods to correct the W1282X-CFTR mutation	17
Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutation	17
CFTR processing, trafficking and interactions	17
Organoids for personalized treatment of Cystic Fibrosis: Professional perspectives on the ethics and governance of organoid biobanking	17
Ursodeoxycholic acid and liver disease associated with cystic fibrosis: A multicenter cohort study	17
Targeted exhaled breath analysis for detection of Pseudomonas aeruginosa in cystic fibrosis patients	16
Ebselen attenuates tobramycin-induced ototoxicity in mice	16
Delayed glucose peak and elevated 1-hour glucose on the oral glucose tolerance test identify youth with cystic fibrosis with lower oral disposition index	16
Evaluating barriers to and promoters of telehealth during the COVID-19 pandemic at U.S. cystic fibrosis programs	16
A longitudinal assessment of non-invasive biomarkers to diagnose and predict cystic fibrosis-associated liver disease	16
Health-related quality-of-life in children with cystic fibrosis aged 5-years and associations with health outcomes	16
Formative evaluation of a dashboard to support coproduction of healthcare services in cystic fibrosis	16
Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis	16
Dissociation of systemic and mucosal autoimmunity in cystic fibrosis	16
ECFS standards of care on CFTR-related disorders: Diagnostic criteria of CFTR dysfunction	16
Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on liver tests at a large single adult cystic fibrosis centre	16
Finding the relevance of antimicrobial stewardship for cystic fibrosis	16
CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation	16
ECFS standards of care on CFTR-related disorders: Updated diagnostic criteria	16
Suicide attempts in adolescents with cystic fibrosis on Elexacaftor/Tezacaftor/Ivacaftor therapy	15
Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor	15
Influence of pre-diabetic and pancreatic exocrine states on pulmonary and nutritional status in adults with Cystic Fibrosis	15
Use of elexacaftor/tezacaftor/ivacaftor in liver transplant patients with cystic fibrosis	15
Barriers and facilitators to implementing telehealth services during the COVID-19 pandemic: A qualitative analysis of interviews with cystic fibrosis care team members	15
Impact of cross-sensitivity error correction on representative nitrogen-based multiple breath washout data from clinical trials	15
Variable cellular ivacaftor concentrations in people with cystic fibrosis on modulator therapy	15
Alpha-1 antitrypsin for cystic fibrosis complicated by severe cytokinemic COVID-19	15
Developing a smartphone application to support social connectedness and wellbeing in young people with cystic fibrosis	15
Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding	15
Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaftor/ivacaftor compared to males	15
Hypervitaminosis A with fulminant secondary intracranial hypertension following personalized medicine-based Elexacaftor/Tezacaftor/Ivacaftor initiation in a preadolescent with cystic fibrosis	15
The genetics and genomics of cystic fibrosis	15
Multicenter prospective study showing a high gastrointestinal symptom burden in cystic fibrosis	15
In vivo demonstration of Pseudomonas aeruginosa biofilms as independent pharmacological microcompartments	15
Microbial interaction: Prevotella spp. reduce P. aeruginosa induced inflammation in cystic fibrosis bronchial epithelial cells	15

Total bacterial load, inflammation, and structural lung disease in paediatric cystic fibrosis	15
Disparities in first evaluation of infants with cystic fibrosis since implementation of newborn screening	15
COVID-19 in lung-transplanted and cystic fibrosis patients: Be careful	15
When CFSPID becomes CF	14
Neutrophil dysfunction in cystic fibrosis	14
Predictors of pulmonary exacerbation treatment in cystic fibrosis	14
Design and methods for understanding the state of cystic fibrosis care amid the COVID-19 pandemic	14
Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation	14
Loss of ciliated cells and altered airway epithelial integrity in cystic fibrosis	14
The prevalence of aberrations in body composition in pediatric cystic fibrosis patients and relationships with pulmonary function, bone mineral density, and hospitalizations	14
To be or not to be on CFTR modulators during pregnancy: Risks to be considered	14
Antibiofilm and mucolytic action of nitric oxide delivered via gas or macromolecular donor using in vitro and ex vivo models	14
Intestinal function and transit associate with gut microbiota dysbiosis in cystic fibrosis	14
Urine lipoarabinomannan as a marker for low-risk of NTM infection in the CF airway	14
The association of pediatric cystic fibrosis-related diabetes screening on clinical outcomes by center: A CF patient registry study	14
Rethinking physical exercise training in the modern era of cystic fibrosis: A step towards optimising short-term efficacy and long-term engagement	14
Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease	14
Antimicrobial resistance: Concerns of healthcare providers and people with CF	13
The cystic fibrosis gut as a potential source of multidrug resistant pathogens	13
Financial impacts of the COVID-19 pandemic on cystic fibrosis care: lessons for the future	13
The impact of chest computed tomography and chest radiography on clinical management of cystic fibrosis lung disease	13
Cystic fibrosis drug trial design in the era of CFTR modulators associated with substantial clinical benefit: stakeholders’ consensus view	13
A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: Effect on mucociliary clearance and clinical outcomes	13
Olfactory dysfunction in cystic fibrosis: Impact of CFTR modulator therapy	13
Minimal change in structural, functional and inflammatory markers of lung disease in newborn screened infants with cystic fibrosis at one year	13
Drug-induced liver injury from elexacaftor/ivacaftor/tezacaftor	13
Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in people with cystic fibrosis and healthy controls	13
Real-world use of ivacaftor in Canada: A retrospective analysis using the Canadian Cystic Fibrosis Registry	13
ACT with CF: A telehealth and in-person feasibility study to address anxiety and depressive symptoms among people with cystic fibrosis	13
Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study	13
Quality of home spirometry performance amongst adults with cystic fibrosis	13
Insights into the variability of nasal potential difference, a biomarker of CFTR activity	13
Designing the GALAXY study: Partnering with the cystic fibrosis community to optimize assessment of gastrointestinal symptoms	13
Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251)	13
Lumacaftor/ivacaftor improves liver cholesterol metabolism but does not influence hypocholesterolemia in patients with cystic fibrosis	13
Outcomes and endpoints reported in studies of pulmonary exacerbations in people with cystic fibrosis: A systematic review	13
VO2max as an exercise tolerance endpoint in people with cystic fibrosis: Lessons from a lumacaftor/ivacaftor trial	13
In vitro 3D culture lung model from expanded primary cystic fibrosis human airway cells	13
Airway profile of bioactive lipids predicts early progression of lung disease in cystic fibrosis	12
Onset of systemic arterial hypertension after initiation of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A case series	12
Effect of lumacaftor-ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis: Results from the PROSPECT MCC sub-study	12
Clinical effects of the three CFTR potentiator treatments curcumin, genistein and ivacaftor in patients with the CFTR-S1251N gating mutation	12
Pseudomonas aeruginosa infection, but not mono or dual-combination CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis	12
Outcomes following lung re-transplantation in patients with cystic fibrosis	12
Cystic fibrosis in black African children in South Africa: a case control study	12
Effects of elexacaftor/tezacaftor/ivacaftor therapy in children with cystic fibrosis – a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI	12
Improved glucose tolerance after initiation of Elexacaftor / Tezacaftor / Ivacaftor in adults with cystic fibrosis	12
Occurrence, outcomes and predictors of portal hypertension in cystic fibrosis: A longitudinal prospective birth cohort study	12
The implementation of an aminoglycoside induced ototoxicity algorithm for people with cystic fibrosis	12
CFTR modulator therapy alters plasma sphingolipid profiles in people with cystic fibrosis	12
Clinical outcomes of a large cohort of individuals with the F508del/5T;TG12 CFTR genotype	12
Entry of cystic fibrosis transmembrane conductance potentiator ivacaftor into the developing brain and lung	12
Screening practices for nontuberculous mycobacteria at US cystic fibrosis centers	12
Addressing the burden of illness in adults with cystic fibrosis with screening and triage: An early intervention model of palliative care	12
Vitamin D supplementation in patients with cystic fibrosis: A systematic review and meta-analysis	12
Nutritional considerations for a new era: A CF foundation position paper	11
Intraoperative extracorporeal membrane oxygenation for lung transplantation in cystic fibrosis patients: Predictors and impact on outcome	11
Modulation, microbiota and inflammation in the adult CF gut: A prospective study	11
Complete CFTR gene sequencing in 5,058 individuals with cystic fibrosis informs variant-specific treatment	11
Defining key outcomes to evaluate performance of newborn screening programmes for cystic fibrosis	11
Incidence and risk factors of cancer in individuals with cystic fibrosis in the UK; a case-control study	11
Circulating CRP and calprotectin to diagnose CF pulmonary exacerbations	11
Dysregulated insulin in pancreatic insufficient cystic fibrosis with post-prandial hypoglycemia	11
Elexacaftor-Tezacaftor-Ivacaftor improve Gastro-Oesophageal reflux and Sinonasal symptoms in advanced cystic fibrosis	11
SLC26A9 SNP rs7512462 is not associated with lung disease severity or lung function response to ivacaftor in cystic fibrosis patients with G551D-CFTR	11
Trends in nontuberculous mycobacteria infection in children and young people with cystic fibrosis	11
Fibrocyte accumulation in the lungs of cystic fibrosis patients	11
Phenotypic characteristics of incident and chronic MRSA isolates in cystic fibrosis	11
Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study	11
Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection	11
Peripheral lung effect of elexacaftor/tezacaftor/ivacaftor in adult cystic fibrosis	11
CFTR: New insights into structure and function and implications for modulation by small molecules	11
Adherence to lumacaftor-ivacaftor therapy in patients with cystic fibrosis in France	11
Forskolin induced swelling (FIS) assay in intestinal organoids to guide eligibility for compassionate use treatment in a CF patient with a rare genotype	11
New concepts in antimicrobial resistance in cystic fibrosis respiratory infections	10
A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a resid	10
The feasibility of home monitoring of young people with cystic fibrosis: Results from CLIMB-CF	10
Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis	10
Nutritional status and lung function in children with pancreatic-sufficient cystic fibrosis	10
Exercise intolerance in cystic fibrosis-the role of CFTR modulator therapies	10
Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation	10
Magnetic resonance imaging of the gastrointestinal tract shows reduced small bowel motility and altered chyme in cystic fibrosis compared to controls	10
EFFECT OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR ON ANNUAL RATE OF LUNG FUNCTION DECLINE IN PEOPLE WITH CYSTIC FIBROSIS	10
Longitudinal changes in lung function following initiation of lumacaftor/ivacaftor combination	10
Clinician variability in the diagnosis and treatment of aspergillus fumigatus-related conditions in cystic fibrosis: An international survey	10
Utilization of electronic patient-reported outcome measures in cystic fibrosis research: Application to the GALAXY study	10
Lumacaftor/ivacaftor in people with cystic fibrosis with an A455E–CFTR mutation	10
Utility of lung clearance index in CF: What we know, what we don't know and musings on how to bridge the gap	10
GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN)	10
Evaluation of the exercise intensity generated by active video gaming in patients with cystic fibrosis and healthy individuals	9
Structured surveillance of Achromobacter, Pandoraea and Ralstonia species from patients in England with cystic fibrosis	9
Standards of care guidance for sweat testing; phase two of the ECFS quality improvement programme	9
Sex differences in treatment patterns in cystic fibrosis pulmonary exacerbations	9
Abnormal glucose tolerance and the 50-gram glucose challenge test in Cystic fibrosis	9
European survey of newborn bloodspot screening for CF: opportunity to address challenges and improve performance	9